Exelixis Gets FDA Approval for Cabometyx in Combination Therapy for Front-Line RCC

Exelixis (NASDAQ:EXEL) is charging into the weekend on a high note. On Friday, the company announced that the Food and Drug Administration approved its drug Cabometyx (also known as Cometriq) for first-line treatment of patients with advanced renal cell carcinoma (RCC), in combination with Bristol Myers Squibb‘s (NYSE:BMY) Opdivo.

The approval is a big win for Exelixis, as RCC is the most common form of kidney cancer. The company also pointed out that it is among the top 10 most diagnosed cancers in the U.S.

Medical professionals conferring in a hospital lobby.

Image source: Getty Images.

The approval cycles of Cabometyx and Opdivo closely align. The Bristol Myers Squibb drug was approved by the FDA as a second-line treatment for RCC in late 2015. Cabometyx was given its green light for the same indication the following April.

The drug’s approval derives from a comparative study on the effects of a Cabometyx/Opdivo combination versus sunitinib — marketed by Pfizer under the brand name Sutent. The drugs were put through their paces in a phase 3 clinical trial aimed at evaluating their effect on previously untreated advanced or metastatic RCC.

“As the only combination treatment regimen to double median progression-free survival and objective response rate compared with sunitinib while also significantly improving overall survival, we are excited that Cabometyx in combination with Opdivo is now available for the first-line treatment of patients with advanced kidney cancer,” said Exelixis CEO Michael Morrissey.

READ:  The Smartest Stocks to Buy With $100 Right Now

Both Exelixis and Bristol Myers Squibb stock increased on the news, although the latter had a more modest rise. Exelixis closed Friday nearly 3.9% higher, against the 0.3% decline of the S&P 500 index, while its peer enjoyed a 0.6% bump on the day.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

View more information: https://www.fool.com/investing/2021/01/22/exelixis-gets-fda-approval-for-cabometyx-in-combin/

Xem thêm bài viết thuộc chuyên mục: investing

Related Articles

Leave a Reply

Back to top button